BioCentury
ARTICLE | Product Development

Breaking through the BBB

October 26, 2009 7:00 AM UTC

The idea of using the brain's own transport receptors to ferry drugs across the blood-brain barrier has been around for more than a decade. AngioChem Inc., one of a new generation of companies trying to take advantage of natural transport molecules in the brain, is the first to report proof-of-concept data on delivering therapeutics across the divide in humans.

The next step will be to find a partner...